Table 1.
Baseline properties for participating patients with metastatic colorectal cancer
| ER + BV + FOLFOX4 (n = 66) | BV + FOLFOX4 (n = 65) | |
|---|---|---|
|
|
||
| Baseline properties | Patients, n (%) | Patients, n (%) |
| Age (years) | ||
| Average (range) | 62.5 (41-75) | 61.8 (38-72) |
| < 60 | 37 (56.1%) | 41 (63.1%) |
| ≥ 60 | 29 (43.9%) | 24 (36.9%) |
| Sex | ||
| Male | 47 (71.2%) | 42 (64.6%) |
| Female | 19 (28.8%) | 23 (35.4%) |
| ECOG PS | ||
| 0 | 32 (48.5%) | 35 (53.8%) |
| 1 | 26 (39.4%) | 22 (33.8%) |
| 2 | 8 (12.1%) | 8 (12.3%) |
| Carcinoma site | ||
| Colon | 43 (65.2%) | 41 (61.5%) |
| Rectum | 20 (30.3%) | 22 (33.8%) |
| Both | 3 (4.5%) | 2 (30.8%) |
| Metastatic sites | ||
| Liver | 27 (40.9%) | 24 (36.9%) |
| Lung | 21 (31.8%) | 25 (38.5%) |
| Lymph | 13 (19.7%) | 12 (18.5%) |
| Others | 5 (7.6%) | 4 (6.2%) |
| Number of metastatic sites | ||
| 1 | 50 (75.8%) | 53 (81.5%) |
| ≥ 2 | 16 (24.2%) | 12 (18.5%) |
| First-line chemotherapy | ||
| 5-FU | 25 (37.9%) | 20 (30.8%) |
| FOLFIRI | 23 (34.8%) | 32 (49.2%) |
| XELOX | 18 (27.3%) | 13 (20.0%) |
Abbreviations: ER, erlotinib; BV, bevacizumab; ECOG PS, Eastern Cooperative Oncology Group Performance Status.